Cotargeting HSP90 and its client proteins for treatment of prostate cancer

Molecular Cancer Therapeutics

Volumn 15, Issue 9, 2016, Pages 2107-2118

  Chen, Long ^a   Li, Jie ^a   Farah, Elia ^a   Sarkar, Sukumar ^b   Ahmad, Nihal ^c   Gupta, Sanjay ^d   Larner, James ^b   Liu, Xiaoqi ^a,e  

^a PURDUE UNIVERSITY   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Purdue University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BETA ACTIN; ENZALUTAMIDE; GELDANAMYCIN; HEAT SHOCK PROTEIN 40; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; LAMIN A; LAMIN C; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; POLO LIKE KINASE 1; PROSTATE SPECIFIC ANTIGEN; TANESPIMYCIN; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E3; ANDROGEN RECEPTOR ANTAGONIST; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; CELL CYCLE PROTEIN; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN BINDING; PROTEIN SERINE THREONINE KINASE;

ANDROGEN DEPRIVATION THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CELL KILLING; DRUG EFFICACY; DRUG POTENTIATION; ENZYME DEGRADATION; FEMALE; HEK293 CELL LINE; HELA CELL LINE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UBIQUITINATION;

ANDROGEN RECEPTOR ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS; CARRIER PROTEINS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MALE; MICE; MOLECULAR TARGETED THERAPY; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84990874015     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-16-0241     Document Type: Article

References (52)

1. Matsumoto T, Sakari M, Okada M, Yokoyama A, Takahashi S, Kouzmenko A, et al. The androgen receptor in health and disease. Annu Rev Physiol 2013;75:201-24.
2. Foley C, Mitsiades N. Moving beyond the androgen receptor (AR): Targeting AR-interacting proteins to treat prostate cancer. Horm Cancer 2016;7:84-103.
3. Gudziak MR, Smith AY. Hormonal therapy for stage D cancer of the prostate. West J Med 1994;160:351-9.
4. Perlmutter MA, Lepor H. Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev Urol 2007;9:S3-S8.
5. Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: Mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 2013;32:5501-11.
6. Lonergan PE, Tindall DJ. Androgen receptor signaling in prostate cancer development and progression. J Carcinog 2011;10:20.
7. Attard G, Cooper CS, De Bono JS. Steroid hormone receptors in prostate cancer: A hard habit to break? Cancer Cell 2009;16:458-62.
8. Marques RB, Dits NF, Erkens-Schulze S, Van Weerden WM, Jenster G. Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models. PLoS ONE 2010;5:e13500.
9. Claessens F, Helsen C, Prekovic S, Van Den Broeck T, Spans L, Van Poppel H, et al. Emerging mechanisms of enzalutamide resistance in prostate cancer. Nat Rev Urol 2014;11:712-6.
10. Tyagi N, Tyagi R. The wonderous chaperones: A highlight on therapeutics of cancer and potentially malignant disorders. J Oral Maxillofac Pathol 2015;19:212-20.
11. Tatokoro M, Koga F, Yoshida S, Kihara K. Heat shock protein 90 targeting therapy: State of the art and future perspective. EXCLI J 2015;14:48-58.
12. Neckers L. Heat shock protein 90: the cancer chaperone. J Biosci 2007;32:517-30.
13. Lyman SK, Crawley SC, Gong R, Adamkewicz JI, McGrath G, Chew JY, et al. High-Content, high-throughput analysis of cell cycle perturbations induced by the HSP90 Inhibitor XL888. PLoS ONE 2011;6:e17692.
14. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45.
15. Solit DB, Scher HI, Rosen N. Hsp90 as a therapeutic target in prostate cancer. Sem Oncol 2003;30:709-16.
16. Centenera MM, Fitzpatrick AK, Tilley WD, Butler LM. Hsp90: Still a viable target in prostate cancer. Biochim Biophys Acta Rev Cancer 2013;1835:211-8.
17. DeBoer C, Meulman PA, Wnuk RJ, Peterson DH. Geldanamycin, a new antibiotic. J Antibiot 1970;23:442-7.
18. Mimnaugh EG, Chavany C, Neckers L. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem 1996;271:22796-801.
19. Saif MW, Erlichman C, Dragovich T, Mendelson D, Toft D, Burrows F, et al. Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino) - 17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors. Cancer Chemother Pharmacol 2013;71:1345-55.
20. Whitesell L, Lin NU. HSP90 as a platform for the assembly of more effective cancer chemotherapy. Biochim Biophys Acta 2012;1823:756-66.
21. Gartner EM, Silverman P, Simon M, Flaherty L, Abrams J, Ivy P, et al. A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer. Breast Cancer Res Treat 2012;131:933-7.
22. Pacey S, Gore M, Chao D, Banerji U, Larkin J, Sarker S, et al. A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. Invest New Drugs 2012;30:341-9.
23. He S, Smith DL, Sequeira M, Sang J, Bates RC, Proia DA. The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer. Invest New Drugs 2014;32:577-86.
24. Petronczki M, Lénárt P, Peters J-M. Polo on the rise-frommitotic entry to cytokinesis with Plk1. Dev Cell 2008;14:646-59.
25. Strebhardt K. Multifaceted polo-like kinases: Drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 2010;9:643-60.
26. Zhang Z, Hou X, Shao C, Li J, Cheng JX, Kuang S, et al. Plk1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer. Cancer Res 2014;74:6635-47.
27. Chen YJ, Lai KC, Kuo HH, Chow LP, Yih LH, Lee TC. HSP70 colocalizes with PLK1 at the centrosome and disturbs spindle dynamics in cells arrested in mitosis by arsenic trioxide. Arch Toxicol 2014;88:1711-23.
28. Chen YJ, Lin YP, Chow LP, Lee TC. Proteomic identification of Hsp70 as a new Plk1 substrate in arsenic trioxide-induced mitotically arrested cells. Proteomics 2011;11:4331-45.
29. De Carcer G. Heat shock protein 90 regulates the metaphase-anaphase transition in a polo-like kinase-dependent manner. Cancer Res 2004;64:5106-12.
30. Connell P, Ballinger CA, Jiang J, Wu Y, Thompson LJ, Hohfeld J, et al. The co-chaperone CHIP regulates protein triage decisions mediated by heatshock proteins. Nat Cell Biol 2001;3:93-6.
31. Kundrat L, Regan L. Identification of residues on Hsp70 and Hsp90 ubiquitinated by the cochaperone CHIP. J Mol Biol 2010;395:587-94.
32. Muller P, Ruckova E, Halada P, Coates PJ, Hrstka R, Lane DP, et al. Cterminal phosphorylation of Hsp70 and Hsp90 regulates alternate binding to co-chaperones CHIP and HOP to determine cellular protein folding/degradation balances. Oncogene 2013;32:3101-10.
33. He B, Bai S, Hnat AT, Kalman RI, Minges JT, Patterson C, et al. An androgen receptor NH2-terminal conserved motif interacts with the COOH terminus of the Hsp70-interacting protein (CHIP). J Biol Chem 2004;279:30643-53.
34. Rees I, Lee S, Kim H, Tsai FT. The E3 ubiquitin ligase CHIP binds the androgen receptor in a phosphorylation-dependent manner. Biochim Biophys Acta 2006;1764:1073-9.
35. Sarkar S, Brautigan DL, Parsons SJ, Larner JM. Androgen receptor degradation by the E3 ligase CHIP modulates mitotic arrest in prostate cancer cells. Oncogene 2014;33:26-33.
36. Beausoleil SA, Jedrychowski M, Schwartz D, Elias JE, Villen J, Li J, et al. Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci U S A 2004;101:12130-5.
37. Kuruma H, Matsumoto H, Shiota M, Bishop J, Lamoureux F, Thomas C, et al. A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo. Mol Cancer Ther 2013;12:567-76.
38. Centenera MM, Carter SL, Gillis JL, Marrocco-Tallarigo DL, Grose RH, Tilley WD, et al. Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms. Endocr Relat Cancer 2015;22:805-18.
39. Rodriguez-Vida A, Galazi M, Rudman S, Chowdhury S, Sternberg CN. Enzalutamide for the treatment of metastatic castration-resistant prostate cancer. Drug Design Devel Ther 2015;9:3325-39.
40. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res 2013;73:483-9.
41. Bento CF, Fernandes R, Ramalho J, Marques C, Shang F, Taylor A, et al. The chaperone-dependent ubiquitin ligase CHIP Targets HIF-1a for degradation in the presence of methylglyoxal. PLoS ONE 2010;5:e15062.
42. Esser C, Scheffner M, Hohfeld J. The chaperone-associated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation. J Biol Chem 2005;280:27443-8.
43. Li L, Xin H, Xu X, Huang M, Zhang X, Chen Y, et al. CHIP mediates degradation of Smad proteins and potentially regulates Smad-induced transcription. Mol Cell Biol 2004;24:856-64.
44. Neckers L, Workman P. Hsp90 molecular chaperone inhibitors: Are we there yet? Clin Cancer Res 2012;18:64-76.
45. Senn H, Shapiro RS, Cowen LE. Cdc28 provides a molecular link between Hsp90, morphogenesis, and cell cycle progression in Candida albicans. Mol Biol Cell 2012;23:268-83.
46. Shang Y, Xu X, Duan X, Guo J, Wang Y, Ren F, et al. Hsp70 and Hsp90 oppositely regulate TGF-beta signaling through CHIP/Stub1. Biochem Biophys Res Commun 2014;446:387-92.
47. Kang D, Chen J, Wong J, Fang G. The checkpoint protein Chfr is a ligase that ubiquitinates Plk1 and inhibits Cdc2 at the G2 to M transition. J Cell Biol 2002;156:249-60.
48. Metzger T, Kleiss C, Sumara I. CUL3 and protein kinases: Insights from PLK1/KLHL22 interaction. Cell Cycle 2013;12:2291-6.
49. Beck J, Maerki S, Posch M, Metzger T, Persaud A, Scheel H, et al. Ubiquitylationdependent localization of PLK1 in mitosis. Nat Cell Biol 2013;15:430-9.
50. Shao C, Ahmad N, Hodges K, Kuang S, Ratliff T, Liu X. Inhibition of Pololike Kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer. J Biol Chem 2015;290:2024-33.
51. Li Z, Li J, Bi P, Lu Y, Burcham G, Elzey BD, et al. Plk1 Phosphorylation of PTEN causes a tumor-promoting metabolic state. Mol Cell Biol 2014;34:3642-61.
52. Li J, Karki A, Hodges KB, Ahmad N, Zoubeidi A, Strebhardt K, et al. Cotargeting polo-like kinase 1 and the Wnt/beta-catenin signaling pathway in castration-resistant prostate cancer. Mol Cell Biol 2015;35:4185-98.